Longevity Technology

Longevity Technology

How near are we to technology that could allow humans to live much longer lives? Surprisingly close. Our goal is to unite innovators, researchers, insurers, policymakers, practitioners, and commentators to explore the emerging and rapidly expanding field of science and investment that will influence the future of our global population and economy: LONGEVITY.

International
English
Online/Digital

Outlet metrics

Domain Authority
49
Ranking

Global

#261298

United States

#144238

Health/Health

#2848

Traffic sources
Monthly visitors

Articles

  • 1 week ago | longevity.technology | Danny Sullivan

    Get longevity news first on WhatsApp Longevity biotech Yuva Biosciences has inked a development and license agreement with Northstrive Biosciences aimed at advancing pharmaceutical therapies for obesity, type 2 diabetes and other cardiometabolic diseases by targeting mitochondrial dysfunction. The agreement provides YuvaBio with upfront and milestone payments as well as royalties on future sales of therapeutic products developed using the identified compounds.

  • 1 week ago | longevity.technology | Danny Sullivan

    Get longevity news first on WhatsApp US biotech Ventyx Biosciences has reported encouraging top-line results from a Phase 2a study of its NLRP3 inhibitor in patients with early-stage Parkinson’s disease. While the primary focus was to assess safety and tolerability, the trial also yielded positive data on the drug’s pharmacokinetics, pharmacodynamics and clinical effects.

  • 1 week ago | longevity.technology | Danny Sullivan

    Get longevity news first on WhatsApp Last month, hot on the heels of the recent Nature paper on replacement as an aging intervention, we came across Israeli biotech RenewalBio, which had just secured funding from longevity investment fund LongGame.

  • 1 week ago | longevity.technology | Danny Sullivan

    Get longevity news first on WhatsApp Longevity biotech BioAge Labs has announced that it will harness molecular data from the HUNT Biobank in Norway to expand the capabilities of its drug discovery platform.

  • 1 week ago | longevity.technology | Danny Sullivan

    Get longevity news first on WhatsApp US biotech Parallel Bio has secured $21 million in Series A funding to accelerate development of its human-first approach to drug discovery that seeks to provide a more ethical, accurate and efficient alternative to animal testing.

Contact details

Address

123 Example Street

City, Country 12345

Email Patterns

Socials

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Traffic locations